|
Market Closed -
Nasdaq
00:00:00 24/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 1.720 USD | -2.27% |
|
+26.47% | -85.89% |
| 10-09 | Tenax Therapeutics, Inc. Provides Update on Tnx-103 Level and Level-2 Clinical Trials | CI |
| 09-21 | Tenax Therapeutics, Inc.(NasdaqCM:TENX) added to S&P Global BMI Index | CI |
Company Valuation: Tenax Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 26.21 | 4.979 | 6.553 | 218.5 | 494.6 | 98.52 | - | - |
| Change | - | -81.01% | 31.6% | 3,233.86% | 126.39% | -80.08% | - | - |
| Enterprise Value (EV) 1 | 26.21 | 4.979 | 6.553 | 218.5 | 494.6 | -244.1 | 88.32 | 98.52 |
| Change | - | -81.01% | 31.6% | 3,233.86% | 126.39% | -149.35% | 136.19% | 11.55% |
| P/E | -0.66x | -0.3x | -0.71x | -5.38x | -9.1x | -1.18x | -1.15x | -1.07x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0x | 0x | 0.1x | -0.6x | -0.14x | -0.35x | -0.15x |
| Capitalization / Revenue | - | - | - | - | - | - | - | 8.21x |
| EV / Revenue | - | - | - | - | - | - | - | 8.21x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0.8x | -0.45x | -0.8x | -11.2x | -8.77x | 3.21x | -1.01x | -0.94x |
| EV / FCF | - | - | - | - | - | 4.88x | -0.88x | -0.62x |
| FCF Yield | - | - | - | - | - | 20.5% | -113% | -161% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2,528 | -600.8 | -31.04 | -1.15 | -1.34 | -1.452 | -1.5 | -1.608 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | 12 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -32.73 | -11.05 | -8.234 | -19.49 | -56.38 | -75.97 | -87.2 | -104.9 |
| Net income 1 | -32.47 | -11.05 | -7.711 | -17.6 | -52.6 | -72.73 | -84.06 | -99.54 |
| Net Debt 1 | - | - | - | - | - | -342.6 | -10.2 | - |
| Reference price 2 | 1,664.000 | 178.238 | 21.968 | 6.190 | 12.190 | 1.720 | 1.720 | 1.720 |
| Nbr of stocks (in thousands) | 15.8 | 27.9 | 298 | 35,292 | 40,570 | 57,282 | - | - |
| Announcement Date | 29/03/22 | 31/03/23 | 28/03/24 | 25/03/25 | 10/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.18x | - | - | - | 98.52M | |
| 18.83x | 6.63x | 13.18x | 1.58% | 64.69B | |
| 30.16x | 7.93x | 26.43x | 0.05% | 54.78B | |
| 36.79x | 6.53x | 19.51x | 0.88% | 53.49B | |
| 35.59x | 3.45x | 14.87x | -.--% | 45.98B | |
| 49.71x | 5.74x | 31.52x | -.--% | 42.94B | |
| -19.41x | 187.75x | -20.66x | -.--% | 40.08B | |
| 28.93x | 8.21x | 21.27x | 0.37% | 33.52B | |
| 32.66x | 5.97x | 20.09x | -.--% | 23.67B | |
| 27.67x | 5.83x | 15.12x | -.--% | 23.97B | |
| Average | 23.98x | 26.45x | 15.70x | 0.32% | 38.32B | |
| Weighted average by Cap. | 26.71x | 25.32x | 15.93x | 0.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- TENX Stock
- Valuation Tenax Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
